⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ASND News
Ascendis Pharma A/S American Depositary Shares
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
globenewswire.com
ASND
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
ASND
nuEra Cannabis Announces Kushmas Week Deals and Holiday Savings Across Illinois
prnewswire.com
ASND
Ascend Performance Materials Successfully Emerges from Chapter 11
prnewswire.com
ASND
Innovation with Purpose: NASM Launches ClaireAI™, the Industry’s First Trusted Virtual Mentor to Empower Fitness Professionals
globenewswire.com
ASND
Human Growth Hormone Injection Market Size Expected to Reach USD 8.54 Bn by 2035
globenewswire.com
PFE
MRK
LLY
ASND
IPN
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
globenewswire.com
ASND
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics
globenewswire.com
ASND
Ascendis Pharma Reports Third Quarter 2025 Financial Results
globenewswire.com
ASND
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism
globenewswire.com
ASND